CD8A and cancer: Thus, the rGRA6Nt protein adjuvant provides a new pathway in cancer immunotherapy to effectively activate the protective CD8<sup>+</sup> T cells specific for the individual's cancer cells to prevent the recurrence of surgically resected CRC in patients.